Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Novo Nordisk said it had been able to ease some of the restrictions ... Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy ...

So even a billion-dollar-or-so swing in Zepbound's future sales ... Additionally, Lilly could leverage specialty pharmacies or direct-to-patient models to bypass some PBM restrictions.

Orforglipron (pronounced or-for-GLIP-ron) might be a mouthful to say, but Indianapolis-based Eli Lilly and Co. sees this ...

Eli Lilly is working on a new drug, orforglipron, an oral tablet taken once daily, with no dietary restrictions ... Eli Lilly's total sales between Mounjaro and Zepbound were slightly under ...

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

Novo Nordisk has been ceding market share to Eli Lilly, even though Zepbound's dollar sales still trail Wegovy ... the body and doesn't require dietary restrictions like oral semaglutide does ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

The study involved a large clinical trial comparing the drugs that was funded by Eli Lilly, the maker of Zepbound ... option when regulators halted sales of copycat versions that sometimes ...

For now, sales of Lilly’s injectable drugs with tirzepatide are driving the company’s growth. In the first quarter of 2025, Mounjaro had $3.84 billion in revenue and Zepbound $2.31 billion ...